{"id":27281,"date":"2025-06-25T14:00:19","date_gmt":"2025-06-25T14:00:19","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/it\/?page_id=27281"},"modified":"2026-06-22T13:40:18","modified_gmt":"2026-06-22T13:40:18","slug":"progetto","status":"publish","type":"page","link":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/","title":{"rendered":"BRIUMVI\u00ae progetto"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"27281\" class=\"elementor elementor-27281\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-1fedb58 elementor-section-height-min-height elementor-section-items-bottom elementor-section-boxed elementor-section-height-default\" data-id=\"1fedb58\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-17e31c8\" data-id=\"17e31c8\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-f715740 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"f715740\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-23376f7\" data-id=\"23376f7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-147297b elementor-widget elementor-widget-heading\" data-id=\"147297b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">BRIUMVI\u00ae<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-931e027 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"931e027\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6de5ab8\" data-id=\"6de5ab8\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-c4d7b04 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"c4d7b04\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-e32e4bf\" data-id=\"e32e4bf\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2fcf706 jet-breadcrumbs-align-left elementor-widget elementor-widget-jet-breadcrumbs\" data-id=\"2fcf706\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"jet-breadcrumbs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-jet-breadcrumbs jet-blocks\">\n\t\t<div class=\"jet-breadcrumbs\">\n\t\t<div class=\"jet-breadcrumbs__content\">\n\t\t<div class=\"jet-breadcrumbs__wrap\"><div class=\"jet-breadcrumbs__item\"><a href=\"https:\/\/www.neuraxpharm.com\/it\/\" class=\"jet-breadcrumbs__item-link is-home\" rel=\"home\" title=\"Home\">Home<\/a><\/div>\n\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-918c547 elementor-widget elementor-widget-text-editor\" data-id=\"918c547\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>BRIUMVI\u00ae: primo anticorpo anti-CD20 glicoingegnerizzato nella sclerosi multipla (SM)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-3162dfa elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"3162dfa\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-custom\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-4d14856\" data-id=\"4d14856\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-76e3afd elementor-widget elementor-widget-text-editor\" data-id=\"76e3afd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tAnticorpo Anti-CD20 non glicoingegnerizzato\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-38b929e elementor-widget elementor-widget-image\" data-id=\"38b929e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1221\" height=\"857\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2.png\" class=\"attachment-full size-full wp-image-28938\" alt=\"Anticorpo monoclonale IgG con CD20 e recettore Fc\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2.png 1221w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2-300x211.png 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2-1024x719.png 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2-768x539.png 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2-600x421.png 600w\" sizes=\"(max-width: 1221px) 100vw, 1221px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-16982b3 elementor-widget elementor-widget-text-editor\" data-id=\"16982b3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tImmagine elaborata da ref<sup>3<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d5ec6bf elementor-widget elementor-widget-text-editor\" data-id=\"d5ec6bf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Alcune molecole di glucidiche possono interferire con il legame della regione Fc dell&#8217;anticorpo anti-CD20 con il recettore Fc.<sup>1,2<\/sup><br \/>Immagine elaborata da ref<sup>3<\/sup><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-718e12a\" data-id=\"718e12a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-94d9de1 elementor-widget elementor-widget-text-editor\" data-id=\"94d9de1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tBRIUMVI\u00ae \u00e8 un anticorpo anti-CD20 glicoingegnerizzato.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-62c29b7 elementor-widget elementor-widget-image\" data-id=\"62c29b7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1223\" height=\"857\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063551\/briumvi-briumvi-design-img-2-2.png\" class=\"attachment-full size-full wp-image-28939\" alt=\"Anticorpo IgG che lega CD20 su cellula B\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063551\/briumvi-briumvi-design-img-2-2.png 1223w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063551\/briumvi-briumvi-design-img-2-2-300x210.png 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063551\/briumvi-briumvi-design-img-2-2-1024x718.png 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063551\/briumvi-briumvi-design-img-2-2-768x538.png 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063551\/briumvi-briumvi-design-img-2-2-600x420.png 600w\" sizes=\"(max-width: 1223px) 100vw, 1223px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-517f8b0 elementor-widget elementor-widget-text-editor\" data-id=\"517f8b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tImmagine elaborata da ref<sup>3<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5b4b70f elementor-widget elementor-widget-text-editor\" data-id=\"5b4b70f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Grazie ad uno specifico pattern di glicosilazione del frammento Fc, ublituximab mostra un\u2019aumentata affinit\u00e0 per Fc\u03b3RIIIa (CD16) e una maggiore citolisi cellulare anticorpo-dipendente diretta contro le cellule B. Ref<sup>2<\/sup> Ublituximab induce la lisi delle cellule B CD20+ principalmente tramite citotossicit\u00e0 cellulo\u2011mediata anticorpo\u2011dipendente (antibody\u2011dependent cell\u2011mediated cytotoxicity , ADCC) e, in misura minore, tramite citotossicit\u00e0 complemento\u2011dipendente (complement\u2011dependent cytotoxicity CDC).<sup>2<\/sup><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-482dbf8 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"482dbf8\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-73cf0b1\" data-id=\"73cf0b1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-05f89e2 elementor-widget elementor-widget-text-editor\" data-id=\"05f89e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tBRIUMVI\u00ae ha mostrato una deplezione mediana delle cellule B del 97% in 24 ore negli studi clinici di fase<sup>2<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-88cbfcb elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"88cbfcb\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-25c01a2\" data-id=\"25c01a2\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ba1bcfa elementor-widget elementor-widget-image\" data-id=\"ba1bcfa\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"2560\" height=\"955\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1.png\" class=\"attachment-full size-full wp-image-28940\" alt=\"Grafico ULTIMATE I: CD19+ assoluto nel tempo con dosaggi BRIUMVI\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1.png 2560w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1-300x112.png 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1-1024x382.png 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1-768x287.png 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1-1536x573.png 1536w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1-2048x764.png 2048w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063557\/briumvi-briumvi-design-img-3-v3-scaled-1-600x224.png 600w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-fd96750 elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"fd96750\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-c2dd38f\" data-id=\"c2dd38f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-718178a elementor-widget elementor-widget-text-editor\" data-id=\"718178a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tNegli studi clinici, il trattamento con BRIUMVI\u00ae ha determinato:\n\n\u2022 Una riduzione efficace delle cellule B<sup>2<\/sup>\n\n\u2022 Una rapida riduzione delle cellule B entro 24 ore<sup>2<\/sup>\n\n\u2022 Una riduzione costante delle cellule B fino alla settimana<sup>2<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f73824b elementor-widget elementor-widget-text-editor\" data-id=\"f73824b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tVideo sulla modalit\u00e0 d&#8217;azione di BRIUMVI\u00ae\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-17feaad elementor-widget elementor-widget-jet-video\" data-id=\"17feaad\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"jet-video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-jet-video jet-elements\">\n<div class=\"jet-video jet-video--fa5-compat jet-video-aspect-ratio jet-video-aspect-ratio--16-9\" data-settings=\"{&quot;lightbox&quot;:false,&quot;autoplay&quot;:false}\"><iframe class=\"jet-video-iframe\" allowfullscreen allow=\"autoplay;encrypted-media\" title=\"youtube Video Player\" data-lazy-load=\"https:\/\/www.youtube.com\/embed\/VHMKBoGS0Pw?feature=oembed&amp;playlist=VHMKBoGS0Pw&amp;wmode=opaque&amp;autoplay=0&amp;loop=1&amp;controls=1&amp;mute=1&amp;rel=0&amp;modestbranding=0\"><\/iframe>\n<div class=\"jet-video__overlay jet-video__overlay--custom-bg\" style=\"background-image: url(https:\/\/i.ytimg.com\/vi_webp\/VHMKBoGS0Pw\/maxresdefault.webp);\">\n<div class=\"jet-video__play-button\" role=\"button\" tabindex=\"0\" aria-label=\"Video play button\"><span class=\"jet-elements-icon jet-video__play-button-icon\"><i aria-hidden=\"true\" class=\"fas fa-play\"><\/i><\/span>\t<span class=\"elementor-screen-only\">Play Video<\/span>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4252563 elementor-widget elementor-widget-text-editor\" data-id=\"4252563\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t&nbsp;\n\n<style>\n    .reference-list {<br \/>      display: flex;<br \/>      flex-direction: column;<br \/>      gap: 1em;<br \/>    }<\/p>\n<p>    .reference-item {<br \/>      display: flex;<br \/>      align-items: flex-start;<br \/>    }<\/p>\n<p>    .reference-number {<br \/>      font-size: smaller;<br \/>      margin-right: 5px;<br \/>      vertical-align: super;<br \/>    }<\/p>\n<p>    .reference-text {<br \/>      text-align: left; \/* Alineaci\u00f3n a la izquierda *\/<br \/>    }<br \/>  <\/style>\n\n&nbsp;\n<div class=\"reference-list\">\n<div class=\"reference-item\"><strong>Riferimenti<\/strong><br>\n<span class=\"reference-number\"><sup>1<\/sup><\/span>\n<span class=\"reference-text\">Briumvi\u00ae. RCP<\/span><\/div>\n<div class=\"reference-item\"><span class=\"reference-number\"><sup>2<\/sup><\/span>\n<span class=\"reference-text\">Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N\nEngl J Med. 2022; 387(8): 704-714.doi:10.1056\/NEJMoa2201904.\n<\/span><\/div>\n<div class=\"reference-item\"><span class=\"reference-number\"><sup>3<\/sup><\/span>\n<span class=\"reference-text\">Supplement to: Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing\nmultiple sclerosis. N Engl J Med 2022;387:704-14. DOI: 10.1056\/NEJMoa2201904\n<\/span><\/div>\n<div class=\"reference-item\"><span class=\"reference-number\"><sup>4<\/sup><\/span>\n<span class=\"reference-text\">Sun Y, Izadi S, Callahan M, et al. Antibody-receptor interactions mediate antibody-dependent cellular\ncytotoxicity. J Biol Chem. 2021; 297(1): 100826. doi:10.1016\/j.jbc.2021.100826.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5bacbc5 elementor-widget elementor-widget-text-editor\" data-id=\"5bacbc5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Codice materiale: MAT-IT-BRI-0004-1<br \/>Depositato AIFA: 16\/03\/2026<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-224c842 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"224c842\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7ab9b1a\" data-id=\"7ab9b1a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-37f5544 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"37f5544\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-745c1b7\" data-id=\"745c1b7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4db1680 elementor-align-center elementor-widget elementor-widget-button\" data-id=\"4db1680\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/8574878.fs1.hubspotusercontent-na1.net\/hubfs\/8574878\/BRIUMVI\/2026\/SMPC\/RIASSUNTO%20Briumvi%20September3rd2025%20COLOR_Print%20pages.pdf\" target=\"_blank\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Consulta il riassunto delle caratteristiche del prodotto<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>BRIUMVI\u00ae Home BRIUMVI\u00ae: primo anticorpo anti-CD20 glicoingegnerizzato nella sclerosi multipla (SM) Anticorpo Anti-CD20 non glicoingegnerizzato Immagine elaborata da ref3 Alcune molecole di glucidiche possono interferire con il legame della regione Fc dell&#8217;anticorpo anti-CD20 con il recettore Fc.1,2Immagine elaborata da ref3 BRIUMVI\u00ae \u00e8 un anticorpo anti-CD20 glicoingegnerizzato. Immagine elaborata da ref3 Grazie ad uno specifico pattern [&hellip;]<\/p>\n","protected":false},"author":2493,"featured_media":0,"parent":27270,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"class_list":["post-27281","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BRIUMVI\u00ae progetto - Neuraxpharm Italia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BRIUMVI\u00ae progetto\" \/>\n<meta property=\"og:description\" content=\"BRIUMVI\u00ae Home BRIUMVI\u00ae: primo anticorpo anti-CD20 glicoingegnerizzato nella sclerosi multipla (SM) Anticorpo Anti-CD20 non glicoingegnerizzato Immagine elaborata da ref3 Alcune molecole di glucidiche possono interferire con il legame della regione Fc dell&#8217;anticorpo anti-CD20 con il recettore Fc.1,2Immagine elaborata da ref3 BRIUMVI\u00ae \u00e8 un anticorpo anti-CD20 glicoingegnerizzato. Immagine elaborata da ref3 Grazie ad uno specifico pattern [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm Italia\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T13:40:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-briumvi-design-img-1-2.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/\",\"name\":\"BRIUMVI\u00ae progetto - Neuraxpharm Italia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/briumvi-briumvi-design-img-1-2.png\",\"datePublished\":\"2025-06-25T14:00:19+00:00\",\"dateModified\":\"2026-06-22T13:40:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/#primaryimage\",\"url\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/06063548\\\/briumvi-briumvi-design-img-1-2.png\",\"contentUrl\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/06063548\\\/briumvi-briumvi-design-img-1-2.png\",\"width\":1221,\"height\":857,\"caption\":\"Anticorpo monoclonale IgG con CD20 e recettore Fc\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/progetto\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portafoglio\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sclerosi multipla Briumvi\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"BRIUMVI\u00ae progetto\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/\",\"name\":\"Neuraxpharm Italia\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BRIUMVI\u00ae progetto - Neuraxpharm Italia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto","og_locale":"it_IT","og_type":"article","og_title":"BRIUMVI\u00ae progetto","og_description":"BRIUMVI\u00ae Home BRIUMVI\u00ae: primo anticorpo anti-CD20 glicoingegnerizzato nella sclerosi multipla (SM) Anticorpo Anti-CD20 non glicoingegnerizzato Immagine elaborata da ref3 Alcune molecole di glucidiche possono interferire con il legame della regione Fc dell&#8217;anticorpo anti-CD20 con il recettore Fc.1,2Immagine elaborata da ref3 BRIUMVI\u00ae \u00e8 un anticorpo anti-CD20 glicoingegnerizzato. Immagine elaborata da ref3 Grazie ad uno specifico pattern [&hellip;]","og_url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/","og_site_name":"Neuraxpharm Italia","article_modified_time":"2026-06-22T13:40:18+00:00","og_image":[{"url":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-briumvi-design-img-1-2.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"2 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/","url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/","name":"BRIUMVI\u00ae progetto - Neuraxpharm Italia","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/#primaryimage"},"thumbnailUrl":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-briumvi-design-img-1-2.png","datePublished":"2025-06-25T14:00:19+00:00","dateModified":"2026-06-22T13:40:18+00:00","breadcrumb":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/#primaryimage","url":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2.png","contentUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06063548\/briumvi-briumvi-design-img-1-2.png","width":1221,"height":857,"caption":"Anticorpo monoclonale IgG con CD20 e recettore Fc"},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/progetto\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portafoglio","item":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/"},{"@type":"ListItem","position":2,"name":"Sclerosi multipla Briumvi","item":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/"},{"@type":"ListItem","position":3,"name":"BRIUMVI\u00ae progetto"}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/it\/#website","url":"https:\/\/www.neuraxpharm.com\/it\/","name":"Neuraxpharm Italia","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/users\/2493"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/comments?post=27281"}],"version-history":[{"count":21,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27281\/revisions"}],"predecessor-version":[{"id":29190,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27281\/revisions\/29190"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27270"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/media?parent=27281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}